In a striking intersection of biotechnology and artificial intelligence, Valthos Inc. has emerged from stealth with a $30 million seed financing round—led by the OpenAI Startup Fund, Lux Capital and Founders Fund—to build what it calls the “tech stack for biodefense.” Founded by Kathleen McMahon (previously head of Life Sciences at Palantir Technologies) and Tess…
BridGene Biosciences, a San Jose–based biotech innovator focused on tackling traditionally “undruggable” molecular targets, has raised $28 million in a Series B+ funding round led by Bayland Capital. This capital injection will accelerate clinical advancement of BridGene’s lead candidate, BGC-515—a covalent TEAD inhibitor aimed at solid tumors—and fuel expansion of its proprietary IMTAC™ chemoproteomic platform…
In a decisive move for the interventional oncology space, ABK Biomedical has closed an oversubscribed US$35 million Series D round, led by J.P. Morgan Life Sciences Private Capital. Longtime backers including F‑Prime, Santé Ventures, Eight Roads Ventures, and a strategic but undisclosed medical device player also participated. The fresh capital will underwrite the clinical operations…
In a significant advancement for the biotechnology sector, Shift Bioscience has successfully raised $16 million (£12.5 million) in Seed funding, spearheaded by BGF and joined by prominent existing investors including F-Prime Capital, Kindred Capital, and Jonathan Milner. This investment is poised to accelerate the development of Shift Bioscience’s innovative artificial intelligence platform aimed at identifying…
In a significant stride towards revolutionizing treatments for one of the most challenging pediatric brain tumors, TippingPoint Biosciences has announced the successful closure of pre-seed investments. This funding round has garnered support from renowned organizations, including the Pediatric Brain Tumor Foundation, the Sontag Foundation, the Yuvaan Tiwari Foundation, and BrightEdge, the venture capital arm of…
Arsenal Biosciences, Inc. (ArsenalBio), a pioneering force in programmable cell therapy, has announced the successful closure of an oversubscribed $325 million Series C financing round. This significant funding boost reflects a growing confidence in ArsenalBio’s innovative approach to advanced CAR T-cell therapies targeting solid tumors. The Series C round attracted a host of new investors,…
ZBiotics, a trailblazer in the realm of genetically engineered probiotics, has successfully concluded its $12 million Series A funding round. The investment, led by Spring Tide Capital and supported by Access Capital, Seamless Capital, Goat Rodeo Capital, and Seaside Ventures, marks a significant milestone for the company. The funds are set to fuel ZBiotics‘ plans…
Shinobi Therapeutics, a trailblazer in immune evasive iPS cell therapies, has been awarded up to $59 million in non-dilutive grant funding by the Japanese Agency for Medical Research and Development (AMED). This significant grant will accelerate the development of Shinobi’s pioneering iPS-T cell therapy, aimed at treating GPC3+ solid tumors. Dr. Yasumichi Hitoshi, Chief of…
Jade Biosciences, a biotechnology innovator focused on autoimmune diseases, has announced the successful closing of an $80 million financing round. Led by Fairmount and Venrock Healthcare Capital Partners, with additional contributions from Deep Track Capital, Driehaus Capital Management, Franklin Templeton, RTW Investments, and Braidwell LP, this investment will drive the development of Jade’s cutting-edge therapies…
LTZ Therapeutics, an emerging leader in immunotherapy, has successfully completed a $20 million Series A financing round. This round, spearheaded by new investor Lapam Capital and including significant contributions from GL Ventures, K2 Venture Partners, and Shunwei Capital, brings LTZ’s total funding to approximately $50 million since its inception in 2022. The new capital will…
